GRI Bio files corporate presentation with no material new disclosures

GRI Bio, Inc.

Furnished a corporate presentation dated August 20, 2025 under Regulation FD.
Presentation provides an overview of GRI Bio's approach to inflammatory diseases.
No specific financial results, guidance, or material operational updates were disclosed.
The filing is made under Item 7.01 and is not deemed filed for SEC purposes.
Ticker: GRI; stock trades on Nasdaq Capital Market.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.